AOC2

Across TCGA pan-cancer cohorts, AOC2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AOC2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AOC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AOC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and PRAD are the cancer types where AOC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.500	0.963	<.001	23	view →
UCEC	DFS	Median	All	1.000	0.618	.006	20	view →
PRAD	OS	Median	All	0.157	0.883	<.001	12	view →
BLCA	OS	Median	III,IV	0.164	0.687	<.001	12	view →
LUSC	DFS	Median	II,III,IV	0.079	0.749	.010	12	view →
KIRP	DFS	Median	All	0.218	0.771	.029	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AOC2–BRCA (OS)

Open the BRCA breakdown →